| Literature DB >> 30740597 |
Emma C Hope1, Ron E Crump2, T Deirdre Hollingsworth3, Timo Smieszek4,5, Julie V Robotham4, Koen B Pouwels4,6.
Abstract
BACKGROUND: Seeing one's practice as a high antibiotic prescriber compared to general practices with similar patient populations can be one of the best motivators for change. Current comparisons are based on age-sex weighting of the practice population for expected prescribing rates (STAR-PU). Here, we investigate whether there is a need to additionally account for further potentially legitimate medical reasons for higher antibiotic prescribing.Entities:
Keywords: Anti-bacterial agents; Electronic health records; Epidemiology; General practice; Inappropriate prescribing
Year: 2018 PMID: 30740597 PMCID: PMC6358038 DOI: 10.1016/j.eclinm.2018.12.003
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Oral antibacterial item based STAR-PU weights.
| Age band (y) | Male | Female |
|---|---|---|
| 0–4 | 0.8 | 0.8 |
| 5–14 | 0.3 | 0.4 |
| 15–24 | 0.3 | 0.6 |
| 25–34 | 0.2 | 0.6 |
| 35–44 | 0.3 | 0.6 |
| 45–54 | 0.3 | 0.6 |
| 55–64 | 0.4 | 0.7 |
| 65–74 | 0.7 | 1.0 |
| 75 + | 1.0 | 1.3 |
STAR-PU = Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.
Distribution of included variables and univariate association with number of antibiotics per STAR-PU.
| Median (25th–75th percentile) | Simple linear association with antibiotic/STAR-PU, relative risk (95% CI) | |
|---|---|---|
| Antibiotics per STAR-PU | 1.09 (0.92–1.25) | – |
| Smoking prevalence | 19.77 (17.40–22.82) | 1.014 (1.012–1.015) |
| CHD prevalence | 3.27 (2.50–4.01) | 1.043 (1.037–1.050) |
| Diabetes prevalence | 6.52 (5.53–7.52) | 1.020 (1.016–1.024) |
| HF prevalence | 0.69 (0.49–0.90) | 1.063 (1.042–1.085) |
| Asthma prevalence | 5.99 (5.15–6.81) | 1.048 (1.042–1.054) |
| COPD prevalence | 1.75 (1.23–2.39) | 1.090 (1.081–1.098) |
| Cancer prevalence | 2.22 (1.60–2.77) | 0.983 (0.975–0.992) |
| CKD prevalence | 3.87 (2.67–5.24) | 1.007 (1.004–1.011) |
CHD = chronic heart disease. CKD = chronic kidney disease. COPD = chronic obstructive pulmonary disease. HF = heart failure. STAR-PU = Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.
Estimated associations between predictor variables and number of antibiotics per STAR-PU.
| Predictor | Comorbidity model | Full model |
|---|---|---|
| Asthma prevalence | 1.025 (1.016–1.035) | 1.034 (1.027–1.040) |
| COPD prevalence | 1.070 (1.056–1.084) | 1.059 (1.049–1.068) |
| Diabetes prevalence | 1.008 (1.003–1.014) | 1.002 (0.998–1.006) |
| Smoking prevalence | NA | 1.005 (1.003–1.007) |
| Deprivation 1 | NA | Ref. |
| Deprivation 2 | NA | 1.000 (0.978–1.022) |
| Deprivation 3 | NA | 1.010 (0.987–1.033) |
| Deprivation 4 | NA | 1.044 (1.020–1.069) |
| Deprivation 5 | NA | 1.095 (1.068–1.122) |
COPD = chronic obstructive pulmonary disease. STAR-PU = Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.
Fig. 1Venn diagram of identifying top 20% of practices in terms of antibiotic prescribing rate per STAR-PU using three different methodologies.
The full model considered all variables (blue ellipse, see Table 2), the comorbidity model considered only comorbidities (pink ellipse, see Table 2) and the current methodology is based on ranking practices based on their antibiotic prescribing rate per STAR-PU without taking into account any other variables (yellow ellipse). STAR-PU: Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.
Estimated associations between predictor variables and number of antibiotics per STAR-PU after removing outer 1% in terms of antibiotic prescribing rate per STAR-PU.
| Predictor | Comorbidity model | Full model |
|---|---|---|
| Asthma prevalence | 1.021 (1.016–1.026) | 1.022 (1.017–1.026) |
| COPD prevalence | 1.058 (1.050–1.066) | 1.050 (1.042–1.058) |
| Diabetes prevalence | 1.023 (1.020–1.026) | 1.022 (1.019–1.025) |
| CHD prevalence | 1.028 (1.021–1.035) | 1.029 (1.022–1.036) |
| Smoking prevalence | NA | 1.004 (1.003–1.006) |
CHD = coronary heart disease. COPD = chronic obstructive pulmonary disease. STAR-PU = Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.
Fig. 2Venn diagram of identifying top 20% of practices in terms of antibiotic prescribing rate per STAR-PU using three different methodologies, after removing outer 1% of practices based on antibiotic prescribing rate per STAR-PU.
The full model considered all variables (blue ellipse, see Table 2), the comorbidity model considered only comorbidities (pink ellipse, see Table 2) and the current methodology is based on ranking practices based on their antibiotic prescribing rate per STAR-PU without taking into account any other variables (yellow ellipse). STAR-PU: Specific Therapeutic Group Age-sex weighting Related Prescribing Unit.